Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer

NCT: NCT07290998 · NOT_YET_RECRUITING

NCT IDNCT07290998
StatusNOT_YET_RECRUITING
Start Date2026-05
Completion2029-05

Brief Summary

This is a multi-center clinical study enrolling up to 12 participants . The primary objective of the study is to evaluate the safety of Alpha DaRT for the treatment of locally recurrent prostate cancer . The secondary objectives of the study is to evaluate the efficacy of the Alpha DaRT sources in locally recurrent prostate cancer patients assessed by biochemical and clinical evaluation of disease progression as well as overall survival

Frequently Asked Questions

What is Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer is a clinical trial registered under NCT07290998. Current status: NOT_YET_RECRUITING.

What is the status of NCT07290998?

The current status of NCT07290998 (Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer) is: NOT_YET_RECRUITING.

When did Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer start?

Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer started on 2026-05.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑